SEC Filing Summary: Pfizer Inc (13F-HR)
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Pfizer Inc, acting as an Institutional Investment Manager. The report covers the quarter ended June 30, 2026, and was signed on August 11, 2026, by Madelyn D. Purcell, Assistant General Counsel.
Key Financial Metrics
As a Form 13F-HR, this document discloses equity holdings rather than the company's operational financial performance. Consequently, the filing does not provide data on Pfizer's revenue, profit, cash flow, margins, debt, or liquidity.
- Total Value of Reported Holdings: $170,365,906
- Total Number of Holdings Entries: 20
- Other Included Managers: None
Material Changes
The filing text does not provide comparative data against the prior period (March 31, 2026) to determine material changes in holdings or value. The document lists only the current quarter's snapshot.
Guidance, Outlook, and Risks
This form is a regulatory disclosure of investment positions and does not contain management commentary, future guidance, risk factors, or contingencies regarding Pfizer's business operations.
Key Facts for Investor Verification
- Verify the specific list of 20 equity securities held by Pfizer Inc as of June 30, 2026, which are not detailed in the cover page text provided.
- Confirm that the total reported value of $170,365,906 represents the aggregate market value of these specific holdings.
- Note that this filing reflects Pfizer's role as an investment manager for these specific assets, not its corporate financial health.